Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Etanercept therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Cyclophosphamide therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Azathioprine therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Smoking cessation drug therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of antipyretic |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of sulfonylurea |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of inhalation anesthetic using endotracheal tube |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |
Antineoplastic chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Oral antipsychotic therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of prophylactic eplerenone |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Antifungal therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of prophylactic metolazone |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of prophylactic bendroflumethiazide |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of prophylactic xipamide |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of varicella live vaccine |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |
Administration of human tetanus immune globulin |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Opioid therapy for breathlessness management |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |
Bupropion therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Varenicline therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of vaccine product containing only Neisseria meningitidis serogroup C antigen |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |
Novel oral anticoagulant prophylaxis |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of enema via rectal route |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Leflunomide therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Aspirin therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Amiodarone therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Sulfasalazine therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of vaccine product containing only Neisseria meningitidis serogroup B antigen |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |
Administration of first dose of vaccine product containing only Neisseria meningitidis serogroup B antigen |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |
Administration of second dose of vaccine product containing only Neisseria meningitidis serogroup B antigen |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |
Administration of booster dose of vaccine product containing only Neisseria meningitidis serogroup B antigen |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |
Warfarin therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Calcium channel blocker therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Diuretic therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of vaccine product containing only Neisseria meningitidis serogroup B antigen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of second dose of vaccine product containing only Neisseria meningitidis serogroup B antigen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of booster dose of vaccine product containing only Neisseria meningitidis serogroup B antigen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of vaccine product containing only Neisseria meningitidis capsular polysaccharide antigen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of vaccine product containing only Rabies lyssavirus antigen via intramuscular route |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of vaccine product containing only Salmonella enterica subspecies enterica serovar Typhi capsular polysaccharide Vi antigen via intramuscular route |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of vaccine product containing only live attenuated Measles morbillivirus antigen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of vaccine product containing only inactivated whole Human poliovirus antigen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of vaccine product containing only Human papillomavirus 16 and 18 antigens |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of human papilloma virus type 4 vaccine |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Abatacept therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of vaccine product containing only Human alphaherpesvirus 3 antigen for shingles |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Adalimumab therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
5 |
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
6 |
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
7 |
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
8 |
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
9 |
Rituximab, ifosfamide, carboplatin and etoposide chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
4 |
Rituximab, ifosfamide, carboplatin and etoposide chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
5 |
Rituximab, ifosfamide, carboplatin and etoposide chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
6 |
Rituximab, ifosfamide, carboplatin and etoposide chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
7 |
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
4 |
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
5 |
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
6 |
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
7 |
Oral radionuclide therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
4 |
Anxiolytic drug therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of prophylactic aromatase inhibitor |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Cyclosporine therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Golimumab therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Isotretinoin therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Clozapine therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Cannabis therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Bisphosphonate therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Antibiotic therapy for prevention of recurrent infection |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Leuprorelin therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Mercaptopurine therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Postmenopausal hormone replacement therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Rituximab therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Tacrolimus therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Tamoxifen therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Testosterone cypionate therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Testosterone replacement therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Tocilizumab therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Tofacitinib therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Thyroid hormone replacement therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of first dose of vaccine product containing only Human alphaherpesvirus 3 antigen for chickenpox |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of second dose of vaccine product containing only Human alphaherpesvirus 3 antigen for chickenpox |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of vaccine product containing only Human alphaherpesvirus 3 antigen for shingles |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of vaccine product containing only Human papillomavirus 9 antigen |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Ustekinumab therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Sirolimus therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Lenalidomide therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Belimumab therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Certolizumab pegol therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Apremilast therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Acitretin therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Medicinal gold therapy |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Opiate therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Controlled ovarian stimulation |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of vaccine product containing only Human papillomavirus 6, 11, 16 and 18 antigens |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |
Dipyridamole therapy |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of bisoprolol |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of carvedilol |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of nebivolol |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
1 |
Administration of anesthesia for obstetric procedure |
Method |
True |
Administration - action |
Inferred relationship |
Existential restriction modifier |
2 |
Administration of pneumococcal 7-valent conjugate vaccine |
Method |
False |
Administration - action |
Inferred relationship |
Existential restriction modifier |
3 |